NKTR-214 short attack - Mr. Liu | DVAX Message Board Posts

Dynavax Technologies Corporation

  DVAX website

DVAX   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1401 of 1693  at  11/12/2018 10:05:15 PM  by


The following message was updated on 11/12/2018 10:13:03 PM.

 In response to msg 1400 by  liuyiiv
view thread

Re: NKTR-214 short attack - Mr. Liu

Thank you for the input, I have NKTR for a short term trade, will be out either before earlier Jan, 2019 or its PPS reaching $45...
I would be extremely happy if SD-101 combo could keep ORR 70% and reach CR 20% for its phase III trial...
By the way, just moment ago, I , first time, paid attention to the date presented by 'Changes in Immune Activity in The Tumor Micron-environment', and realized how important those data are for selecting SD-101 2mg dose for all current and future SD-101 trials. Apparently, those SD-101 dose escalation data is benefiting DV281 dose escalation trial to locate best efficacy dose before its phase II expansion trial earlier next year.
Hopefully, AZD1419 will be a great Christmas gift to everyone here

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 159
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
1402 2mg vs. 8 mg ulingt 0 11/13/2018 7:09:39 AM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
Financial Market Data provided by